| Autor: |
Marsham, P. R., Wardleworth, J. M., Boyle, F. T., Hennequin, L. F., Kimbell, R., Brown, M., Jackman, A. L. |
| Zdroj: |
Journal of Medicinal Chemistry; September 23, 1999, Vol. 42 Issue: 19 p3809-3820, 12p |
| Abstrakt: |
The synthesis is described of a series of analogues of the potent thymidylate synthase (TS) inhibitor, N-[4-[N-[(3,4-dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl]-N-prop-2-ynylamino]-2-fluorobenzoyl]-l-glutamic acid (4, ZM214888), in which the glutamic acid moiety is replaced by homologous amino acids and α-amino acids where the ω-carboxylate is replaced by acylsulfonamides and acidic heterocycles. In general these modifications when compared to 4 gave compounds with increased potency as inhibitors of isolated TS and as cytotoxic agents against murine tumor cell lines. The new compounds require transport by the reduced folate carrier for entry into cells but are not converted intracellularly into polyglutamated species. Agents with this profile are expected to show activity against tumors that are resistant to classical antifolates due to low expression of folylpolyglutamate synthetase. The analogue (S)-2-[4-[N-[(3,4-dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl]-N-prop-2-ynylamino]-2-fluorobenzamido]-4-(1H-1,2,3,4-tetrazol-5-yl)butyric acid (35, ZD9331) has been selected as a clinical development candidate and is currently undergoing phase I studies. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
